KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
about
Novel roles for hERG K(+) channels in cell proliferation and apoptosisIdentification of the functional binding pocket for compounds targeting small-conductance Ca2+-activated potassium channelsUnstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+-sensing and SK channel activationGeneral Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMACIdentification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell LinesMucosal potassium efflux mediated via Kcnn4 channels provides the driving force for electrogenic anion secretion in colonInhibition of the K+ channel K(Ca)3.1 reduces TGF-β1-induced premature senescence, myofibroblast phenotype transition and proliferation of mesangial cells.The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors.Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytesHigh glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channelSelective phosphorylation modulates the PIP2 sensitivity of the CaM-SK channel complexThe Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.The Blockage of KCa3.1 Channel Inhibited Proliferation, Migration and Promoted Apoptosis of Human Hepatocellular Carcinoma CellsTherapeutic potential of KCa3.1 blockers: recent advances and promising trends.The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signalingBlockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic miceThe potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.Functional cooperation between KCa3.1 and TRPC1 channels in human breast cancer: Role in cell proliferation and patient prognosis.KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.Ion channels as targets for cancer therapyEndothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.Role of the potassium channel KCa3.1 in diabetic nephropathy.The CNS under pathophysiologic attack--examining the role of K₂p channels.Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?Targeting ion channels for the treatment of autoimmune neuroinflammation.Fused Thiazin-3-ones as KCa3.1 Inhibitors.Role of the K(Ca)3.1 K+ channel in auricular lymph node CD4+ T-lymphocyte function of the delayed-type hypersensitivity model.Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.Effects of clotrimazol on the acute necrotizing pancreatitis in rats.Stabilization of protein-protein interactions in drug discovery.The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.Differential Activity of Voltage- and Ca2+-Dependent Potassium Channels in Leukemic T Cell Lines: Jurkat Cells Represent an Exceptional Case.Ion Channels and Transporters in Inflammation: Special Focus on TRP Channels and TRPC6
P2860
Q27015660-048E161B-873B-4475-85CA-8398B627411AQ27671773-4443062F-0D13-4114-993D-D52141F1C3B7Q27676817-9D235E07-C892-44DB-A451-E70B3C4A18B3Q28385542-BA1640BE-47B7-43A4-8243-34073EF472D5Q28553394-317BBDD2-287E-4A3C-A816-03BBEE07F3FCQ28578786-7B38ECAF-E7E0-4E03-9FA6-7FCBFEBCF9CEQ31149306-98862DEA-DA61-4C58-A05F-E62F36C5631EQ33685939-B6CCA777-BF65-4265-925F-380FE6FEA0F8Q35022931-F0D59E25-DD96-4FBE-B8BC-D76C5F49B9F5Q35147905-D7C80C7A-5D8E-4AAB-8417-72682AAB44C7Q35570980-8C206B91-419E-4AA3-AB40-536D89312661Q35660234-AD78C63C-140D-434A-A153-9C6CF87AFC91Q35739537-5E32D308-3813-4649-B533-054826F3217CQ35944615-55A2F69D-3DCE-4892-A5E0-978912C184DEQ36890651-08916862-85F9-42B5-98E7-9EF48D272A86Q37030987-E5D310B6-5779-4676-B810-688045F9F2E2Q37184567-A01A2762-5AF8-43C6-8C60-0F7DBCB9A855Q37327602-EC3CBE8E-66E7-45C7-9E7C-4169EE8676DFQ37392731-9B60E8B1-727F-456B-879B-3BB927C5DCDEQ37542846-B726F798-29AB-49C4-B5F4-AF6741135A85Q37901394-69BA2C86-2404-4DDF-9D88-478386D754B7Q38056312-D76DF894-A6AE-455D-BB94-73AA3DC365B7Q38223110-532CE98E-0B6A-414E-8A87-E74E4A1F66F7Q38284426-B32C9C90-4CE6-4116-B8EA-4A21B8E6916AQ39264163-5CF6FFC5-80BD-4B4F-A9E7-AD620DF46217Q39357037-48F47B9F-18CE-4214-9D83-FBF6946581EFQ39781434-0A7674D1-9C39-4C46-96C4-1356F907DEB9Q41482329-AD4E70EE-7B1C-4361-B9BA-D866CF43F960Q42180973-46DE8C07-D0E3-4DE8-9267-52C3D23F0F9CQ42247368-905E50B4-791A-4C5F-9D9E-2C8AC855C7E4Q45347204-0119F5CB-9DD7-4C45-9C63-83C10D935164Q47938743-D853DEAA-6709-417D-AD06-9078E019E2A0Q50051379-7CEAB2A8-2C79-40AD-AAA5-112121FB2CBEQ53060403-C3F6FC57-9CBF-4100-85BD-2A0373304EC3Q55057818-7A0B57AD-A0AF-456B-A964-3CF3B1F74A83Q57177158-E9C98750-DD7C-44AC-9AC3-93953348E95D
P2860
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@en
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@nl
type
label
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@en
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@nl
prefLabel
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@en
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@nl
P2093
P2860
P356
P1476
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
@en
P2093
Charles A Lunn
Chuan-Chu Chou
Nicholas J Murgolo
P2860
P304
P356
10.1586/14737159.8.2.179
P577
2008-03-01T00:00:00Z